Avicenna Journal of Clinical Microbiology and Infection

Published by: Kowsar

Response to Various Treatments in the Patients With Chronic Hepatitis B; A Cross-Sectional Study

Authors Information
1 Department of Infectious Diseases, Brucellosis Research Center, Hamadan University of Medical Sciences, Hamadan, IR Iran
Article Notes and Dates
Avicenna Journal of Clinical Microbiology and Infection: May 2014, 1 (1); e19213.Published Online: April 28, 2014
Article Type: Research Article; Received : January 14, 2014; Revised : February 10, 2014; Accepted : March 13, 2014
DOI: http://dx.doi.org/10.17795/ajcmi-19213

To Cite : Mamani M, Majzoobi M M, Eini P, Keramat F. Response to Various Treatments in the Patients With Chronic Hepatitis B; A Cross-Sectional Study, Avicenna J Clin Microb Infec. 2014 ;1(1):e19213. doi: 10.17795/ajcmi-19213.

Copyright: Copyright © 0, Avicenna Journal of Clinical Microbiology and Infection. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990; 8 Suppl-20[PubMed]
  • 2. McMahon BJ. Natural history of chronic hepatitis B - clinical implications. Medscape J Med. 2008; 10(4): 91[PubMed]
  • 3. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990; 263(9): 1218-22[PubMed]
  • 4. Sadi S, Farrohi K, McCollum RW, Le Bouvier GL. Hepatitis-B antigen in Iran: frequency and subtype. Lancet. 1972; 2(7791): 1377-8[PubMed]
  • 5. Tabarestani M, Hoofnagle JH, Afkari A. Type B hepatitis in Iran. Acta Med Iran. 1977; 20(3-4): 105-10[PubMed]
  • 6. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population--a viral marker study. Ann Acad Med Singapore. 1980; 9(2): 144-8[PubMed]
  • 7. Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. J Trop Med Hyg. 1993; 96(5): 277-87[PubMed]
  • 8. Zali MR, Mohammad K, Noorbala AA, Noorimayer B, Shahraz S. Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran. East Mediterr Health J. 2005; 11(1-2): 62-7[PubMed]
  • 9. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 10. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010; 14(3): 253-62[DOI][PubMed]
  • 11. Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis. 1982; 146(2): 198-204[PubMed]
  • 12. Kim WR, Ishitani MR, Dickson ER. Rising burden of Hepatitis B in the United States should'the other'virus be forgotten? Hepatology. 2002; 36(4): 222A
  • 13. Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. N Engl J Med. 1979; 300(3): 101-6[DOI][PubMed]
  • 14. Chu CM, Liaw YF, Pao CC, Huang MJ. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers. Hepatology. 1989; 9(3): 452-6[PubMed]
  • 15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 16. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39(3): 857-61[DOI][PubMed]
  • 17. Planas R, Morillas RM. [Treatment of hepatitis B virus infection: present and future]. Gastroenterol Hepatol. 2008; 31(6): 349-55[PubMed]
  • 18. Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008; 23(8 Pt 1): 1182-92[DOI][PubMed]
  • 19. Juls L, Dinstage K, Urt J, Issel B. Harrison's principles of internal medicine. 2012; : 1822-55
  • 20. Ahmad N, Alam S, Mustafa G, Adnan AB, Baig RH, Khan M. e-antigen-negative chronic hepatitis B in Bangladesh. Hepatobiliary Pancreat Dis Int. 2008; 7(4): 379-82[PubMed]
  • 21. Alavian SM, Daroudi T, Hatami S. [The evaluation of lamivudine treatment efficacy on patients with chronic hepatitis B infection]. Govaresh. 2002; 33(7): 33-7
  • 22. Panahi M, Heidari AA, Rokni F, Teimourzadeh N. [The evaluation of interferon α and lamivudine in the treatment of patients with chronic hepatitis B infection who were irresponsive to lamivudine]. Med J Mashhad Univ Med Sci. 2004; 83(47): 5-10
  • 23. Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology. 2005; 48(6): 341-9[DOI][PubMed]
  • 24. Souto FJ, Piraja AC, da Silva GS, Bottecchia M, Gomes SA. [Long-term use of lamivudine for treating chronic hepatitis B in the State of Mato Grosso]. Rev Soc Bras Med Trop. 2007; 40(1): 18-24[PubMed]
  • 25. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142(4): 240-50[PubMed]
  • 26. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005; 100(11): 2463-71[DOI][PubMed]
  • 27. Asik Akman S, Cokceken Okcu S, Anil OH, Kose S, Bakiler AR. [Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B]. Mikrobiyol Bul. 2006; 40(1-2): 47-53[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Search Relations:


  • Mojgan Mamani: [PubMed] [Scholar]
  • Mohammad Mehdi Majzoobi: [PubMed] [Scholar]
  • Peyman Eini: [PubMed] [Scholar]
  • Fariba Keramat: [PubMed] [Scholar]
  • Related Article in PubMed
  • Related Article in Google Scholar

Create Citiaion Alert via Google Reader